← Leaderboards
Marcus E Peter
University Of Chicago
$21,803,126
Attributed
$22,203,126
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,203,126 · 13
By mechanism
R01$10,770,711 · 6
R35$6,167,005 · 1
P30$3,269,934 · 2
R21$1,195,476 · 2
R41$400,000 · 1
R42$400,000 · 1
Top collaborators
- Robert Schickel2 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Anne I. Sperling$25,843,318
- Shutsung Liao$4,738,143
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsApoptosisCancer CellBasePathway InteractionsCellsTumorCessation Of LifeIn VitroClinicResistanceSignal TransductionIn VivoMediatingMicrornasCancer TherapyNeoplastic CellTumor ProgressionMouse ModelNovel StrategiesTnfrsf6 GeneComplexImmuneReceptor
Grant awards (61)
Shared Resource Management$2,713,641
P30 · FY2025 · CA · contact PI
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer$477,698
R01 · FY2025 · CA · contact PI
Development of a DISE-inducing, short RNA therapeutic to treat ovarian cancer$400,000
R42 · FY2025 · CA
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer$455,145
R01 · FY2024 · CA · contact PI
Development of a novel, RNA-interference-based therapeutic to treat prostate cancer$400,000
R41 · FY2024 · CA
Translational Research in Solid Tumors (TRIST) Research Program$84,449
P30 · FY2024 · CA · contact PI
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer$451,069
R01 · FY2023 · CA · contact PI
Translational Research in Solid Tumors (TRIST) Research Program$84,449
P30 · FY2023 · CA · contact PI
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer$475,275
R01 · FY2022 · CA · contact PI
Translational Research in Solid Tumors (TRIST) Research Program$72,391
P30 · FY2022 · CA · contact PI
DISE - a natural cancer surveillance mechanism - a new road to cancer therapy$913,955
R35 · FY2021 · CA · contact PI
6mer seed toxicity and AIDS$238,500
R21 · FY2021 · AI · contact PI
Translational Research in Solid Tumors (TRIST) Research Program$72,391
P30 · FY2021 · CA · contact PI
DISE - a natural cancer surveillance mechanism - a new road to cancer therapy$913,955
R35 · FY2020 · CA · contact PI
6mer seed toxicity and AIDS$197,500
R21 · FY2020 · AI · contact PI
Translational Research in Solid Tumors (TRIST) Research Program$72,391
P30 · FY2020 · CA · contact PI
DISE - a natural cancer surveillance mechanism - a new road to cancer therapy$886,536
R35 · FY2019 · CA · contact PI
Translational Research in Solid Tumors (TRIST) Research Program$72,391
P30 · FY2019 · CA · contact PI
DISE - a natural cancer surveillance mechanism - a new road to cancer therapy$913,955
R35 · FY2018 · CA · contact PI
Translational Research in Solid Tumors (TRIST) Research Program$73,827
P30 · FY2018 · CA · contact PI
Translational Research in Solid Tumors (TRIST) Research Program$8,620
P30 · FY2018 · CA · contact PI
Translational Research in Solid Tumors (TRIST) Research Program$8,488
P30 · FY2018 · CA · contact PI
Translational Research in Solid Tumors (TRIST) Research Program$6,896
P30 · FY2018 · CA · contact PI
DISE - a natural cancer surveillance mechanism - a new road to cancer therapy$913,955
R35 · FY2017 · CA · contact PI
DICE - a natural cancer surveillance mechanism - a new road to cancer therapy$913,955
R35 · FY2016 · CA · contact PI
DICE - a natural cancer surveillance mechanism - a new road to cancer therapy$710,694
R35 · FY2015 · CA · contact PI
Fas protects cancer stem cells from death$353,419
R01 · FY2015 · CA · contact PI
The role of Fas as tumor promoter$285,323
R01 · FY2014 · CA · contact PI
The Role of MicroRNAs in Tumor Progression$263,917
R01 · FY2014 · CA · contact PI
The role of Fas as tumor promoter$276,499
R01 · FY2013 · CA · contact PI
The Role of MicroRNAs in Tumor Progression$255,800
R01 · FY2013 · CA · contact PI
The role of Fas as tumor promoter$294,148
R01 · FY2012 · CA · contact PI
The Role of MicroRNAs in Tumor Progression$272,177
R01 · FY2012 · CA · contact PI
The role of Fas as tumor promoter$294,148
R01 · FY2011 · CA · contact PI
The Role of MicroRNAs in Tumor Progression$283,051
R01 · FY2011 · CA · contact PI
Novel Fas/CD95 Signaling Mechanisms$264,833
R01 · FY2011 · CA · contact PI
The Role of MicroRNAs in Tumor Progression$283,343
R01 · FY2010 · CA · contact PI
Novel Fas/CD95 Signaling Mechanisms$273,024
R01 · FY2010 · CA · contact PI
The Role of MicroRNAs in Tumor Progression$15,291
R01 · FY2010 · CA · contact PI
The Role of CD95 as a Tumor Promoter$288,390
R01 · FY2009 · CA · contact PI
Novel Fas/CD95 Signaling Mechanisms$275,709
R01 · FY2009 · CA · contact PI
The Role of CD95 as a Tumor Promoter$288,390
R01 · FY2008 · CA · contact PI
Novel Fas/CD95 Signaling Mechanisms$275,709
R01 · FY2008 · CA · contact PI
The Role of CD95 as a Tumor Promoter$287,453
R01 · FY2007 · CA · contact PI
Molecular Characterization of the Two CD95 Pathways$274,512
R01 · FY2007 · GM · contact PI
The Role of CD95 as a Tumor Promoter$296,039
R01 · FY2006 · CA · contact PI
Molecular Characterization of the Two CD95 Pathways$282,710
R01 · FY2006 · GM · contact PI
Novel CD95 Signaling Mechanisms$265,071
R01 · FY2006 · CA · contact PI
The Role of CD95 as a Tumor Promoter$301,188
R01 · FY2005 · CA
Molecular Characterization of the Two CD95 Pathways$289,513
R01 · FY2005 · GM
Novel CD95 Signaling Mechanisms$271,450
R01 · FY2005 · CA
Molecular Characterization of the Two CD95 Pathways$289,513
R01 · FY2004 · GM
Novel CD95 Signaling Mechanisms$271,450
R01 · FY2004 · CA
Fas Internalization and Beta Cells$379,738
R21 · FY2003 · AI
Novel CD95 Signaling Mechanisms$271,450
R01 · FY2003 · CA
MOLECULAR CHARACTERIZATION OF THE TWO CD95 PATHWAYS$252,918
R01 · FY2003 · GM
Fas Internalization and Beta Cells$379,738
R21 · FY2002 · AI
Novel CD95 Signaling Mechanisms$271,450
R01 · FY2002 · CA
MOLECULAR CHARACTERIZATION OF THE TWO CD95 PATHWAYS$253,431
R01 · FY2002 · GM
MOLECULAR CHARACTERIZATION OF THE TWO CD95 PATHWAYS$252,790
R01 · FY2001 · GM
MOLECULAR CHARACTERIZATION OF THE TWO CD95 PATHWAYS$237,415
R01 · FY2000 · GM